Medtronic Launches System Performance Guarantee for Payers and Employers

Medtronic plc (NYSE:MDT), the global leader in medical
technology, today announced the launch of the MiniMed(TM) 670G Performance
Guarantee Program – an outcomes-based offering for payers and employers designed
to mitigate costs for diabetes-related complications. With this Guarantee,
Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4
years for qualifying diabetes-related inpatient hospitalization and emergency
room admissions for eligible in-network patients in the United States.

“This new program demonstrates the strong confidence we have in our ability to
deliver improved clinical outcomes with our MiniMed670G system and our
commitment to value-based healthcare that not only improves outcomes but drives
down the enormous burden of diabetes-related healthcare costs,” said Alejandro
Galindo, president of the Advanced Insulin Management division within the
Diabetes Group at Medtronic. “Medtronic is committed to working with new
partners, in new ways, to create a paradigm shift in healthcare so that
incentives are based on delivering better outcomes and quality of care for our
patients.”

The program will provide an opportunity for Medtronic to work with payer and
employer partners to identify patients who would benefit from the MiniMed 670G
system, including those who may be most at-risk for diabetes-related adverse
events. Given Medtronic’s comprehensive suite of products and services,
including offerings like the standalone Guardian(TM) Connect continuous glucose
monitoring system, the company is well positioned to identify these patients and
transition them to the MiniMed 670G system, where they will be supported by our
existing patient engagement program.

The MiniMed 670G system, featuring SmartGuard(TM) technology and Guardian(TM)
Sensor 3, is the world’s first self-adjusting insulin pump that delivers
personalized amounts of basal insulin every 5 minutes based on real-time sensor
glucose values. A growing and compelling body of both real-world and clinical
trial data demonstrate improved Time in Range (the percentage of time spent in
the optimal glycemic range of 70-180 mg/dL), A1C (a marker of blood sugar
control over time) and Quality of Life for people using the system to manage
their type 1 diabetes. SmartGuard technology is the only algorithm available
anywhere in the world with the ability to reduce the risk of hypoglycemia by 44
percent, stabilize glucose at recommended levels, and minimize blood sugar
variability.(1)

“In-patient admissions are a major driver of costs in the diabetes population,
particularly among patients on multiple daily injections.(2) The innovative
technology and strong clinical performance behind our MiniMed 670G system makes
us the only company uniquely positioned to offer this tangible guarantee on
outcomes,” said Suzanne Winter, vice president of the Americas region for the
Diabetes Group at Medtronic. “We believe this will be a compelling value
proposition for payers and employers, as we create a new industry standard for
diabetes contracting that can lead to improved health outcomes, contained costs
and improved quality of life for diabetes patients. We look forward to
establishing this novel program with our payer and employer partners.”

https://bit.ly/2lHu3xW